Hawthorn Pharmaceuticals, Inc. Receives FDA Approval On Granisol™ Oral Solution

Good news for chemotherapy patients perhaps with some side effect relief...BD 

Hawthorn Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) approval of the company's Granisol™ (granisetron HCl) Oral Solution. Granisol™ is an oral solution for the prevention of nausea and vomiting associated with cancer therapy. Granisol™ is the AA-rated equivalent of Roche's Kytril® Oral Solution.

Granisol™ (granisetron HCl) is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and with radiation, including total body irradiation and fractionated abdominal radiation.

Hawthorn Pharmaceuticals, Inc. Receives FDA Approval On Granisol™ Oral Solution